Editas Medicine Inc (EDIT)vsRegeneron Pharmaceuticals Inc (REGN)
EDIT
Editas Medicine Inc
$2.95
+13.46%
HEALTHCARE · Cap: $396.24M
REGN
Regeneron Pharmaceuticals Inc
$813.27
-0.35%
HEALTHCARE · Cap: $81.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 32949% more annual revenue ($15.53B vs $47.01M). REGN leads profitability with a 27.9% profit margin vs -157.3%. REGN earns a higher WallStSmart Score of 66/100 (B-).
EDIT
Avoid31
out of 100
Grade: F
REGN
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EDIT.
Margin of Safety
+42.1%
Fair Value
$1389.86
Current Price
$813.27
$576.59 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 232.3% year-over-year
Conservative balance sheet, low leverage
Strong operational efficiency at 33.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -70.2% — below average capital efficiency
Weak financial health signals
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : EDIT
The strongest argument for EDIT centers on Revenue Growth, Debt/Equity. Revenue growth of 232.3% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 27.9% and operating margin at 33.1%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : EDIT
The primary concerns for EDIT are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
EDIT profiles as a hypergrowth stock while REGN is a growth play — different risk/reward profiles.
EDIT carries more volatility with a beta of 2.00 — expect wider price swings.
EDIT is growing revenue faster at 232.3% — sustainability is the question.
REGN generates stronger free cash flow (334M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (66/100 vs 31/100), backed by strong 27.9% margins and 16.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Editas Medicine Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?